Food and Drug Administration
The committee will discuss the Implications of recently available data related
to the safety of long-acting beta-agonist bronchodilators.
statements contained in this document(s) are those of the product's sponsor,
and FDA does not necessarily agree with the sponsor's statements..
Portions of this document have
been determined to be exempt from disclosure under the Freedom of Information
Act (the FOIA) (5 U.S.C. §552).
These redacted portions will appear as white space on the screen or on the printed page.